← Leaderboards

Linda J Van Eldik

Johns Hopkins University

Google Scholar ↗PubMed ↗ORCID ↗

$37,023,709

Attributed

$51,629,247

Total exposure

25

Grants

21

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.9M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$100,423,224 · 29

By mechanism

P30$44,821,197 · 11

R01$17,473,817 · 5

P01$15,515,684 · 5

U01$11,115,687 · 2

T32$6,125,452 · 3

RF1$2,872,820 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Takashi Tsukamoto$11,312,957
Barbara Stauch Slusher$18,499,514
Rana Rais$2,718,642
Kevin John Whaley$16,227,655
Deborah J Anderson$20,708,269

Others in their field

Top investigators on “Alzheimer&Apos”

Jose A Luchsinger · Columbia University Health Sciences$56,595,040
Eric M Reiman · Banner Health$48,982,487
Yadong Huang · J. David Gladstone Institutes$40,311,515
Lindsay A. Farrer · Boston University Medical Campus$34,189,802
David M Holtzman · Washington University$28,985,806
Michael W Weiner · Northern California Institute Res &Educ$28,197,224

Research focus

Alzheimer&AposS DiseaseDementiaProgramsBrainResearch PersonnelUniversitiesImpaired CognitionKentuckySuccessFundingTranslational ResearchFutureResourcesClinical ResearchPreventTrainingAgingCommunitiesInnovationNeuropathologyAreaPre-ClinicalClinical Trials

Grant awards (153)

University of Kentucky Alzheimer's Disease Research Center$2,801,205

P30 · FY2025 · AG · contact PI

BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial$1,354,624

R01 · FY2025 · AG

GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$815,581

U01 · FY2025 · AG

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$440,849

T32 · FY2025 · AG · contact PI

Core A: University of Kentucky Alzheimer's Disease Core Center$278,795

P30 · FY2025 · AG · contact PI

Core G: University of Kentucky Alzheimer's Disease Core Center$76,948

P30 · FY2025 · AG · contact PI

University of Kentucky Alzheimer's Disease Research Center$2,823,825

P30 · FY2024 · AG · contact PI

BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial$2,140,865

R01 · FY2024 · AG

GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,546,636

U01 · FY2024 · AG

GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,370,663

U01 · FY2024 · AG

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$551,112

T32 · FY2024 · AG · contact PI

Core A: University of Kentucky Alzheimer's Disease Core Center$278,795

P30 · FY2024 · AG · contact PI

Core G: University of Kentucky Alzheimer's Disease Core Center$163,348

P30 · FY2024 · AG · contact PI

University of Kentucky Alzheimer's Disease Research Center$2,880,877

P30 · FY2023 · AG · contact PI

BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial$1,941,017

R01 · FY2023 · AG

GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,547,324

U01 · FY2023 · AG

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$524,414

T32 · FY2023 · AG · contact PI

Core A: University of Kentucky Alzheimer's Disease Core Center$278,795

P30 · FY2023 · AG · contact PI

Core G: University of Kentucky Alzheimer's Disease Core Center$163,348

P30 · FY2023 · AG · contact PI

University of Kentucky Alzheimer's Disease Research Center$2,937,009

P30 · FY2022 · AG · contact PI

BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial$1,966,656

R01 · FY2022 · AG

GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease$1,546,977

U01 · FY2022 · AG

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$508,754

T32 · FY2022 · AG · contact PI

Core A: University of Kentucky Alzheimer's Disease Core Center$278,796

P30 · FY2022 · AG · contact PI

Portable and modular UDS Data Collection software to increase collaboration and engagement of Alzheimerâs Disease Research Center research software engineers$229,258

P30 · FY2022 · AG · contact PI

Core G: University of Kentucky Alzheimer's Disease Core Center$163,348

P30 · FY2022 · AG · contact PI

University of Kentucky Alzheimer's Disease Research Center$3,009,939

P30 · FY2021 · AG · contact PI

BEACH: Biomarker and Edema Attenuation in IntraCerebral Hemorrhage Phase 2a Trial$2,078,174

R01 · FY2021 · AG

First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,193,602

R01 · FY2021 · AG · contact PI

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$498,916

T32 · FY2021 · AG · contact PI

Core A: University of Kentucky Alzheimer's Disease Core Center$355,296

P30 · FY2021 · AG · contact PI

First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$336,600

R01 · FY2021 · AG · contact PI

Core G: University of Kentucky Alzheimer's Disease Core Center$120,148

P30 · FY2021 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$2,138,054

P30 · FY2020 · AG · contact PI

First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,505,935

R01 · FY2020 · AG · contact PI

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$492,423

T32 · FY2020 · AG · contact PI

UK-ADRC neuroimaging supplement: LATE and PART$367,200

P30 · FY2020 · AG · contact PI

Core A: Administrative Core$228,542

P30 · FY2020 · AG · contact PI

Research Education Component (RL5)$94,591

P30 · FY2020 · AG · contact PI

Pre-clinical efficacy of a selective p38MAPK inhibitor in a model of comorbid Alzheimer/vascular pathology$2,872,820

RF1 · FY2019 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$2,147,234

P30 · FY2019 · AG · contact PI

First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation$1,403,277

R01 · FY2019 · AG · contact PI

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$473,860

T32 · FY2019 · AG · contact PI

Microglia responses to CNS injury: targeting p38 MAPK signaling$329,219

R01 · FY2019 · NS · contact PI

Core A: Administrative Core$228,542

P30 · FY2019 · AG · contact PI

Research Education Component (RL5)$94,591

P30 · FY2019 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,655,500

P30 · FY2018 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$482,554

P30 · FY2018 · AG · contact PI

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$460,624

T32 · FY2018 · AG · contact PI

Microglia responses to CNS injury: targeting p38 MAPK signaling$329,219

R01 · FY2018 · NS · contact PI

Core A: Administrative Core$228,542

P30 · FY2018 · AG · contact PI

Research Education Component (RL5)$94,591

P30 · FY2018 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,655,500

P30 · FY2017 · AG · contact PI

Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,468,850

U01 · FY2017 · AG · contact PI

Microglia responses to CNS injury: targeting p38 MAPK signaling$329,219

R01 · FY2017 · NS · contact PI

Core A: Administrative Core$228,542

P30 · FY2017 · AG · contact PI

Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)$223,687

T32 · FY2017 · AG

Research Education Component (RL5)$94,591

P30 · FY2017 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,655,500

P30 · FY2016 · AG · contact PI

Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,403,404

U01 · FY2016 · AG · contact PI

Microglia responses to CNS injury: targeting p38 MAPK signaling$329,219

R01 · FY2016 · NS · contact PI

Core A: Administrative Core$228,542

P30 · FY2016 · AG · contact PI

Research Education Component (RL5)$94,591

P30 · FY2016 · AG · contact PI

Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD$1,416,252

U01 · FY2015 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,309,812

P30 · FY2015 · AG · contact PI

Clinical Core$587,007

P30 · FY2015 · AG · contact PI

Microglia responses to CNS injury: targeting p38 MAPK signaling$329,036

R01 · FY2015 · NS · contact PI

Administrative Core$212,682

P30 · FY2015 · AG · contact PI

Biostatistics and Data Management Core$209,643

P30 · FY2015 · AG · contact PI

Neuropathology Core$166,108

P30 · FY2015 · AG · contact PI

Education and Information Transfer Core$134,372

P30 · FY2015 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,353,678

P30 · FY2014 · AG · contact PI

Clinical Core$605,159

P30 · FY2014 · AG · contact PI

Administrative Core$221,938

P30 · FY2014 · AG · contact PI

Biostatistics and Data Management Core$216,130

P30 · FY2014 · AG · contact PI

Neuropathology Core$171,579

P30 · FY2014 · AG · contact PI

Education and Information Transfer Core$138,872

P30 · FY2014 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,269,329

P30 · FY2013 · AG · contact PI

Clinical Core$566,017

P30 · FY2013 · AG · contact PI

Modulation of CNS Proinflammatory Cytokine Production$276,485

R01 · FY2013 · NS · contact PI

Administrative Core$210,144

P30 · FY2013 · AG · contact PI

Biostatistics and Data Management Core$202,151

P30 · FY2013 · AG · contact PI

Neuropathology Core$160,799

P30 · FY2013 · AG · contact PI

Education and Information Transfer Core$130,218

P30 · FY2013 · AG · contact PI

Beta Amyloid and Oxidative Stress in Alzheimer's Disease$1,821,007

P01 · FY2012 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,360,603

P30 · FY2012 · AG · contact PI

Clinical Core$648,129

P30 · FY2012 · AG · contact PI

Modulation of CNS Proinflammatory Cytokine Production$286,513

R01 · FY2012 · NS · contact PI

Administrative Core$253,312

P30 · FY2012 · AG · contact PI

Biostatistics and Data Management Core$241,462

P30 · FY2012 · AG · contact PI

Neuropathology Core$195,606

P30 · FY2012 · AG · contact PI

Education and Information Transfer Core$161,445

P30 · FY2012 · AG · contact PI

Beta Amyloid and Oxidative Stress in Alzheimer's Disease$1,821,001

P01 · FY2011 · AG · contact PI

University of Kentucky Alzheimer's Disease Core Center$1,363,922

P30 · FY2011 · AG · contact PI

Clinical Core$605,157

P30 · FY2011 · AG · contact PI

Modulation of CNS Proinflammatory Cytokine Production$286,513

R01 · FY2011 · NS · contact PI

Administrative Core$230,310

P30 · FY2011 · AG · contact PI

Biostatistics and Data Management Core$216,130

P30 · FY2011 · AG · contact PI

Neuropathology Core$172,374

P30 · FY2011 · AG · contact PI

Education and Information Transfer Core$139,951

P30 · FY2011 · AG · contact PI

Beta Amyloid and Oxidative Stress in Alzheimer's Disease$1,863,989

P01 · FY2010 · AG · contact PI

ALZHEIMER'S DISEASE CORE CENTER$1,294,246

P30 · FY2010 · AG · contact PI

Modulation of CNS Proinflammatory Cytokine Production$292,359

R01 · FY2010 · NS · contact PI

Beta Amyloid and Oxidative Stress in Alzheimer's Disease$1,809,945

P01 · FY2009 · AG · contact PI

ALZHEIMER'S DISEASE CORE CENTER$1,274,260

P30 · FY2009 · AG · contact PI

ALZHEIMER'S DISEASE CORE CENTER$241,715

P30 · FY2009 · AG · contact PI

Molecular Mechanisms and Modulation of Glial Activation$194,409

R37 · FY2009 · AG · contact PI

Molecular Mechanisms and Modulation of Glial Activation$5,000

R37 · FY2009 · AG · contact PI

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$194,409

R37 · FY2008 · AG · contact PI

Drug Discovery Training in Age-Related Disorders$30,655

T32 · FY2008 · AG · contact PI

Molecular Mechanisms and Modulation of Glial Activation$5,000

R37 · FY2008 · AG · contact PI

ROLE OF GLIA IN NEURONAL DEGENERATION$1,449,700

P01 · FY2007 · AG · contact PI

GLIAL CYTOKINES AND NEURONAL DEATH$364,484

P01 · FY2007 · AG · contact PI

Drug Discovery Training in Age-Related Disorders$210,475

T32 · FY2007 · AG · contact PI

Molecular Mechanisms and Modulation of Glial Activation$198,376

R37 · FY2007 · AG · contact PI

CORE--STATISTICAL AND ADMINISTRATIVE$111,469

P01 · FY2007 · AG · contact PI

Molecular Mechanisms and Modulation of Glial Activation$5,000

R37 · FY2007 · AG · contact PI

ROLE OF GLIA IN NEURONAL DEGENERATION$1,233,805

P01 · FY2006 · AG · contact PI

GLIAL CYTOKINES AND NEURONAL DEATH$226,770

P01 · FY2006 · AG · contact PI

Role of Glia in Neuronal Degeneration (Supplemental Application Binder Proj 2)$216,881

P01 · FY2006 · AG · contact PI

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$204,301

R37 · FY2006 · AG · contact PI

Drug Discovery Training in Age-Related Disorders$137,235

T32 · FY2006 · AG · contact PI

CORE--STATISTICAL AND ADMINISTRATIVE$69,047

P01 · FY2006 · AG · contact PI

Drug Discovery Academic Research Experience(DARE)$44,822

R25 · FY2006 · GM · contact PI

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$5,000

R37 · FY2006 · AG · contact PI

ROLE OF GLIA IN NEURONAL DEGENERATION$1,446,399

P01 · FY2005 · AG

Drug Discovery Training in Age-Related Disorders$303,744

T32 · FY2005 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$209,218

R37 · FY2005 · AG

ROLE OF GLIA IN NEURONAL DEGENERATION$75,000

P01 · FY2005 · AG

Drug Discovery Academic Research Experience(DARE)$43,516

R25 · FY2005 · GM

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$5,000

R37 · FY2005 · AG

ROLE OF GLIA IN NEURONAL DEGENERATION$1,404,268

P01 · FY2004 · AG

Drug Discovery Training in Age-Related Disorders$303,744

T32 · FY2004 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$257,250

R37 · FY2004 · AG

Molecular mechanisms of Glial S100 in Neuroinflammation$253,570

R01 · FY2004 · AG

Drug Discovery Academic Research Experience(DARE)$42,249

R25 · FY2004 · GM

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$5,000

R37 · FY2004 · AG

ROLE OF GLIA IN NEURONAL DEGENERATION$1,400,762

P01 · FY2003 · AG

Drug Discovery Training in Age-Related Disorders$293,257

T32 · FY2003 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$257,250

R37 · FY2003 · AG

Molecular mechanisms of Glial S100 in Neuroinflammation$255,163

R01 · FY2003 · AG

Drug Discovery Academic Research Experience(DARE)$41,017

R25 · FY2003 · GM

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$5,000

R37 · FY2003 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$257,250

R37 · FY2002 · AG

Molecular mechanisms of Glial S100 in Neuroinflammation$256,552

R01 · FY2002 · AG

DRUG DISCOVERY TRAINING IN AGE-RELATED DISORDERS$186,731

T32 · FY2002 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$5,000

R37 · FY2002 · AG

DRUG DISCOVERY TRAINING IN AGE-RELATED DISORDERS$260,542

T32 · FY2001 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$257,250

R37 · FY2001 · AG

AB-DERIVED ACTIVE LIGANDS AND GLIAL INTERACTIONS$0

P01 · FY2001 · AG

MOLECULAR MECHANISMS AND MODULATION OF GLIAL ACTIVATION$257,250

R37 · FY2000 · AG

DRUG DISCOVERY TRAINING IN AGE-RELATED DISORDERS$224,430

T32 · FY2000 · AG

AB-DERIVED ACTIVE LIGANDS AND GLIAL INTERACTIONS$201,157

P01 · FY2000 · AG